Login to Your Account

Clinic roundup

Tuesday, May 6, 2014

Advaxis Inc., of Princeton, N.J, said it plans to start a clinical development program with ADXS-cHER2, an immunotherapy candidate designed to target the HER2 oncogene, for the treatment of pediatric osteosarcoma.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription